Shots: 

• Hoth Therapeutics to get exclusive rights to evaluate UMB’s retinamides (RAMBAs) with an option to license the product to develop & commercialize therapies in the fields of dermatology and oncology 
• The focus of the agreement is to develop UMB’s novel retinamide Retinoic acid metabolism blocking agents (RAMBAs) therapies for cancer and dermatological diseases
• UMB’s RAMBAs are anticancer agents works against ATRA in cells providing therapeutic benefits to dermatological diseases including acne- eczema- psoriasis- cold sores- wounds- burns- sunburn- ichthyosis- skin cancer- and Kaposi's Sarcoma

Ref: Hoth Therapeutics | Image: Plexuss